Toronto, Ontario – August 14, 2012,
Theralase Technologies Inc. (TSX-V: TLT) announced today that it is will be
featured on “The Next Biggest Winner”, a television series devoted to discovering
undervalued companies with the ability to grow significantly in shareholder value
and become a big winner as an investment opportunity.
The TV show, "The Next
Biggest Winner," which showcases companies with significant growth
potential is scheduled to air its in-depth interview with Roger Dumoulin-White,
President and CEO of Theralase Technologies Inc. on the iChannel, Tuesday,
August 14th at 7:30pm. The iChannel has over 1.3 million affluent Canadian
subscribers who look to its business programming for new investment
opportunities. For an advance preview, please visit http://www.thenextbiggestwinner.com/theralase-technologies-inc/
.
Roger Dumoulin-White, President and
CEO of Theralase stated, “Being recognized by “The Next Biggest Winner” underscores
the unlocked value and growth potential of Theralase in the near term. The
Company has made impressive strides in the development of both our therapeutic
laser therapy medical device business and our cancer therapy business.” Mr.
Dumoulin-White went on to say that “Investor, shareholder and customer
communication is one of our key mandates for the second half of 2012. In
addition to our news releases, Theralase will publish a quarterly newsletter
and has created active social media pages on Twitter, Facebook, LinkedIn and communicate
weekly via a Theralase Blog.” Please visit www.Twitter.com/theralase, www.Facebook.com/theralase,
www.LinkedIn.com/theralase and www.Blogspot.com/theralase to review these sites.
To our investors, shareholders,
customers and friends of Theralase our 2011 Annual Report is online at our
corporate website at http://www.theralase.com/documents/theralase_2011_annual_report_2011.pdf
and is filed on SEDAR.
About Theralase Technologies Inc.
Theralase Technologies Inc.,
founded in 1995, designs, develops, manufactures and markets patented,
superpulsed laser technology utilized in biostimulation and biodestruction
applications. Theralase technology is safe and effective in treating pain,
inflammation and for tissue regeneration of neural muscular skeletal conditions
and tissue healing in both humans and animals. Theralase develops patented
Photo Dynamic Compound (PDC) technology focused at targeting and destroying
cancers, bacteria and viruses when light activated by Theralase’s proprietary
and patented laser technologies.
For further information please
visit www.theralase.com , regulatory
filings may be viewed by visiting www.sedar.com.
This press release contains
forward-looking statements which reflect the Company's current expectations regarding
future events. The forward-looking statements involve risks and uncertainties.
Actual results could differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy
of this release.
For More Information
Roger Dumoulin-White
President & CEO,
416-447-8455 ext. 225
Greg Bewsh
Director of Investor
Relations,
416-447-8455 ext. 262
No comments:
Post a Comment